We founded InvestAcure because Alzheimer’s must be cured!
Our vision is to see a world where drug companies are owned by millions of spare change investors committed to curing Alzheimer's.
We believe that by bringing together a vast community of cure motivated spare
change investors, brilliant scientists and well-managed companies, we can ensure
that cutting edge scientific discoveries are turned into a lifesaving cure for
Social entrepreneur who built RAJE, a large educational non-profit and had the idea for InvestAcure when his daughter was battling cancer.
Lawrence Pine COO
COO Worked with Max as the COO of RAJE and joined him in co-founding the new company. MBA & IT background.
Alex Geis Lead Tech Advisor
Lead Tech Advisor Founded 21Productions, licensed software to leading universities, CTO at TruOptik
Chief Investment Officer
NGN Capital, Co-
founder & Managing
General Partner, voted
analyst by Institutional
Investor Magazine, Wall
Street Analyst Hall of
Fame, MBA, Harvard
EVP of Development, InvestAcure Foundation
Experienced nonprofit & social impact executive, Founder of Nextdor, a social impact startup accelerator & Bizrael a leading nonprofit, connecting US & Israeli pharmaceutical & tech startups.
George Perry, PH.D Scientific Advisor
Editor-in-Chief of Journal of Alzheimer's, Dean UT-San Antonio, one of the top most-cited scientists in Neuroscience.
Pierre Tariot, MD
Director of the Banner Alzheimer’s Institute. Over 350 scientific papers, including several leading to FDA approval of treatments for Alzheimer's.
Hugo Geerts, PH.D Scientific Advisor
CSO of In Silico Biosciences, headed Johnson & Johnson Alzheimer’s research and developed one of only 5 approved Alzheimer’s drugs.
Adeboye Adejare, PH.D Scientific Advisor
NIH and Alzheimer’s Association national panels. Over 50 publications, 5 patents, and more than 100 presentations at conferences.
J. Thomas Vaughan, Ph.D Scientific Advisor
Columbia University – Director of MR Research – 45 patents – pioneer in development of MRI technology for diagnosis of Alzheimer’s.
Lon Schneider, Ph.D
Director of USC State of California Alzheimer’s Disease Center and the National Institute on Aging Alzheimer’s Disease Research Center. Editor-in-chief of Alzheimer’s & Dementia: Translational Research and Clinical Interventions.
Douglas J MacNeil, Ph.D
A leading expert in early-stage drug discovery directed Exploratory & Translational Sciences at Merck, scientific board of Alzheimer's Drug Discovery Foundation, 144 research publications.
Julie Fleming, Purle Sherpa CEO & Founder Advisor
Julie is a former patent litigator with a science background, and founder of a law-firm business consultancy. Julie’s father is a retired lawyer with Alzheimer’s and vascular dementia.
Beau Mann, Sober Grid CEO & Founder
Beau is an avid entrepreneur – starting and advising several digital companies. Member of the Forbes Technology Council and has been featured in the NY Times, Inc. Magazine, Entrepreneur Magazine, just to name a few.
Sign up today and find out how you can help build a world without Alzheimer’s.
Disclosure: The investacure.com website is owned and operated by InvestAcure, PBC. Investacure PBC does not provide investment advice; any investment advice is provided by InvestAcure, LLC an SEC-registered investment advisor, which is a wholly owned subsidiary of InvestAcure, PBC.